{
    "clinical_study": {
        "@rank": "4882", 
        "arm_group": {
            "arm_group_label": "clonazepam conversion to clobazam (Onfi)", 
            "arm_group_type": "Experimental", 
            "description": "Subject's clonazepam will be converted to clobazam (Onfi). This is an open label study without placebo control."
        }, 
        "brief_summary": {
            "textblock": "The purpose of the study is to examine the clinical safety, tolerability, and efficacy of\n      clobazam (Onfi) when it replaces the pre-existing clonazepam therapy in patients with\n      refractory epilepsy."
        }, 
        "brief_title": "Evaluation of Onfi Conversion Therapy Replacing Clonazepam in Patients With Medically Refractory Epilepsy", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Refractory Epilepsy", 
        "condition_browse": {
            "mesh_term": "Epilepsy"
        }, 
        "detailed_description": {
            "textblock": "The study is designed to answer frequently asked questions when clinicians replace existing\n      1,4-benzodiazepine to Onfi, as follows:\n\n        1. What should be the optimal equivalent doses for conversion?\n\n        2. How quickly should it be converted?\n\n        3. Would there be significant improvement of seizure control?\n\n        4. Should we expect difference in tolerability? If so, what are common adverse events?\n\n        5. Would the tolerance to the therapeutic effect differ with Onfi after conversion?"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject has a confirmed diagnosis of medically refractory epilepsy with or without\n             secondary generalization for at least 12 months prior to the initial study visit.\n\n          -  Currently taking stable dosing regimen of clonazepam (0.5-4mg daily) for seizure\n             control.\n\n          -  Takes at least one additional Anti-epileptic drug besides benzodiazepine.\n\n          -  Age 18-70 years, inclusive.\n\n          -  In opinion of investigator, can be safely treated with Onfi.\n\n          -  Minimum of 2 seizures, but no more than 24 complex partial or generalized seizures,\n             during the 8-week baseline period prior to study entry.\n\n          -  Able to communicate effectively with study personnel and considered reliable, able,\n             willing, and cooperative with regard to complying with protocol-defined requirements,\n             including completion of study diary.\n\n        Exclusion Criteria:\n\n          -  Clinically relevant current illness or history of that may interfere with the\n             subject's ability to complete the study as determined by the investigator.\n\n          -  History of status epilepticus within 6 months prior to the initial study visit.\n\n          -  History of suicidal attempts or suicidal ideation within 12 months of initial visit."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "21", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01932502", 
            "org_study_id": "13BN001"
        }, 
        "intervention": [
            {
                "arm_group_label": "clonazepam conversion to clobazam (Onfi)", 
                "description": "Subject's clonazepam will be converted to the following Onfi doses per day:\nClonazepam 0.5mg converted to Onfi 10mg first week, then titrated up to 40mg per day.\nClonazepam 1.0-2.0mg converted to Onfi 20mg first week, then titrated up to 40mg per day.\nClonazepam 2-4mg converted to Onfi 20mg first week, then titrated up to 60mg per day.\nInitial conversion will occur over two weeks followed by upward titration of up to 10mg increment per week toward the target dose. Down titration of up to 10mg will be allowed during the study.\nThe following will be the initial conversion schedule from clonazepam to Onfi:\nWeek 1: 50% reduction of clonazepam and starting dose of Onfi, replacing the reduced clonazepam dose with the conversion rate of clonazepam 0.5mg = Onfi 10mg.\nWeek 2: Discontinuing clonazepam and increasing the dosage of Onfi by two-fold. Week 3+: Titrate the dose of Onfi up to 40mg per day as tolerated", 
                "intervention_name": "clobazam (Onfi)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "clonazepam conversion to clobazam (Onfi)", 
                "description": "Initial conversion will occur over two weeks followed by upward titration of up to 10mg increment per week toward the target dose. Down titration of up to 10mg will be allowed during the study.", 
                "intervention_name": "Initial conversion and titration", 
                "intervention_type": "Drug", 
                "other_name": "clobazam (Onfi)"
            }, 
            {
                "arm_group_label": "clonazepam conversion to clobazam (Onfi)", 
                "description": "The following will be the initial conversion schedule from clonazepam to Onfi:\nWeek 1: 50% reduction of clonazepam and starting dose of Onfi, replacing the reduced clonazepam dose with the conversion rate of clonazepam 0.5mg=Onfi 10mg.", 
                "intervention_name": "Conversion schedule - Week 1", 
                "intervention_type": "Drug", 
                "other_name": "clobazam (Onfi)"
            }, 
            {
                "arm_group_label": "clonazepam conversion to clobazam (Onfi)", 
                "description": "Week 2: Discontinuing clonazepam and increasing the dosage of Onfi by two-fold.", 
                "intervention_name": "Conversion schedule - Week 2", 
                "intervention_type": "Drug", 
                "other_name": "clobazam (Onfi)"
            }, 
            {
                "arm_group_label": "clonazepam conversion to clobazam (Onfi)", 
                "description": "Week 3+: Titrate the dose of Onfi up to 40mg per day as tolerated.", 
                "intervention_name": "Conversion schedule - Week 3", 
                "intervention_type": "Drug", 
                "other_name": "clobazam (Onfi)"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Clobazam", 
                "Clonazepam"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "epilepsy", 
            "Onfi", 
            "clonazepam"
        ], 
        "lastchanged_date": "April 16, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Phoenix", 
                    "country": "United States", 
                    "state": "Arizona", 
                    "zip": "85013"
                }, 
                "name": "St. Joseph's Hospital and Medical Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Evaluation of Onfi Conversion Therapy Replacing Clonazepam in Patients With Medically Refractory Epilepsy: Efficacy, Tolerability, Dosing Equivalence, and Retention Rate", 
        "overall_official": {
            "affiliation": "St. Joseph's Hospital and Medical Center, Phoenix", 
            "last_name": "Steve Chung, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Efficacy will be measured by percentage of mean seizure reduction averaged over 28 days.", 
            "measure": "Efficacy", 
            "safety_issue": "No", 
            "time_frame": "28 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01932502"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Retention rate, which indirectly measures the therapeutic tolerance, will be measured at 6 weeks, 12 weeks, 24 weeks, and 52 weeks.", 
                "measure": "Tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "Weeks 6 - 52 after medication conversion"
            }, 
            {
                "description": "Retention rate of Onfi at 6-months and 12-months.", 
                "measure": "Retention", 
                "safety_issue": "No", 
                "time_frame": "52 weeks"
            }
        ], 
        "source": "St. Joseph's Hospital and Medical Center, Phoenix", 
        "sponsors": {
            "collaborator": {
                "agency": "H. Lundbeck A/S", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "St. Joseph's Hospital and Medical Center, Phoenix", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}